ClinicalTrials.gg
Active, not recruitingNCT06646055Updated Mar 9, 2026

AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer

A Phase 1/2 interventional study of AK112, Cadonilimab, nab-paclitaxel, gemcitabine and AK112, Cadonilimab, nab-paclitaxel, gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by Akeso. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by Akeso · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This trial is a Phase Ib/II study. All patients are stage IV pancreatic cancer (PDAC) patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. The purpose of this study is to evaluate the safety and efficacy of AK112 and Cadonilimab combined with chemotherapy as first-line treatment for patients with metastatic pancreatic cancer.

02

Conditions studied

  • Metastatic Pancreatic Ductal Adenocarcinoma
03

In context

Lead sponsor

Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be able and willing to provide written and to comply with all requirements of study participation (including all study procedures).
  2. ≥18 years old and ≤ 75 years (regardless of sex).
  3. performance status 0-1
  4. longer than 3 months.
  5. or cytologically confirmed diagnosis of pancreatic ductal carcinoma (PDAC).
  6. No prior systemic anti-tumor therapy for metastatic PDAC.
  7. Adequate organ function.
  8. based on (RECIST) 1.1.

Exclusion criteria

Exclusion Criteria:

  1. Histological or cytological diagnosis of other pathological types.
  2. BRCA1/2 or PALB2 mutations.
  3. Participating in another clinical research.
  4. Active central nervous system (CNS) .
  5. Undergoing systemic antiangiogenic therapy.
  6. Acute or subacute pancreatitis.
  7. Other known within five years.
  8. Active infection requiring systemic therapy.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Cadonilimab(q4w) + AK112 + nab-paclitaxel + gemcitabine(phase Ib)

    Cadonilimab will be administered at a selected dose every 4 weeks (q4w). AK112 will be administed at a fixed dose every 2 weeks (q2w). Nab-paclitaxel and gemcitabine will be administed at 125mg/m2 d1, d8, d15 q4w, and 1000mg/m2 d1, d8, d15 q4w, intravenously respectively.

    Drug: AK112, Cadonilimab, nab-paclitaxel, gemcitabine

  • Experimental
    Cadonilimab(q2w) + AK112 + nab-paclitaxel + gemcitabine(phase Ib)

    Cadonilimab will be administered at a selected dose every 2 weeks (q2w). AK112 will be administed at a fixed dose every 2 weeks (q2w). Nab-paclitaxel and gemcitabine will be administed at 125mg/m2 d1, d8, d15 q4w, and 1000mg/m2 d1, d8, d15 q4w, intravenously respectively.

    Drug: AK112, Cadonilimab, nab-paclitaxel, gemcitabine

  • Experimental
    Cadonilimab + AK112 + nab-paclitaxel + gemcitabine(phase II)

    Cadonilimab will be administered at a selected dose and frequency from phase Ib. AK112 will be administered at a fixed dose every 2 weeks (q2w). Nab-paclitaxel and gemcitabine will be administed at 125mg/m2 d1, d8, d15 q4w, and 1000mg/m2 d1, d8, d15 q4w, intravenously respectively.

    Drug: AK112, Cadonilimab, nab-paclitaxel, gemcitabine

  • Experimental
    AK112 + nab-paclitaxel + gemcitabine(phase II)

    AK112 will be administered at a fixed dose every 2 weeks (q2w). Nab-paclitaxel and gemcitabine will be administed at 125mg/m2 d1, d8, d15 q4w, and 1000mg/m2 d1, d8, d15 q4w, intravenously respectively.

    Drug: AK112, nab-paclitaxel, gemcitabine

  • Active comparator
    nab-paclitaxel + gemcitabine(phase II)

    Nab-paclitaxel and gemcitabine will be administed at 125mg/m2 d1, d8, d15 q4w, and 1000mg/m2 d1, d8, d15 q4w, intravenously respectively.

    Drug: nab-paclitaxel, gemcitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Frequency of adverse events (AEs) and serious adverse events (SAEs)

    Frequency of AEs and SAEs for all Arms in phase Ib.

    Time frame: 28days+28days

  2. Overall Response Rate (ORR)

    ORR is the proportion of subjects with complete response(CR) or partial response(PR) , based on RECIST v1.1.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Pharmacokinetics (PK)

    PK parameters: serum concentrations of AK112 and Cadonilimab at different point of time

    Time frame: Up to Cycle 12

  2. Anti-Drug Antibodies(ADAs)

    Number and percentage of patients with detectable anti-drug antibodies

    Time frame: Up to approximately 2 years

  3. Progression-Free Survival (PFS)

    Evaluation of PFS based on RECIST v1.1.

    Time frame: Up to approximately 2 years

  4. Overall survival (OS)

    Evaluation of OS based on RECIST v1.1.

    Time frame: Up to approximately 2 years

  5. Disease control rate (DCR)

    Evaluation of DCR based on RECIST v1.1.

    Time frame: Up to approximately 2 years

  6. Duration of Response (DoR)

    Evaluation of DoR based on RECIST v1.1.

    Time frame: Up to approximately 2 years

  7. Time to Response (TTR)

    Evaluation of TTR based on RECIST v1.1.

    Time frame: Up to approximately 2 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2024
First posted
Oct 17, 2024
StartActual
Jan 21, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2027
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06646055
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Oct 17, 2024
Start date
Jan 21, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Mar 9, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ivonescimab · Cadonilimab · Albumin-Bound Paclitaxel · Gemcitabine

Start the discussion